Aprepitant: The evidence for its place in the prevention of chemotherapy-induced nausea and vomiting

Core Evidence

Volumn 2, Issue 1, 2007, Pages 15-30

  Chrisp, Paul ^a  

^a Core Medical Publishing ^*  (United Kingdom)

Author keywords

Aprepitant; Chemotherapy; Evidence; Nausea; Vomiting

Indexed keywords

2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; APREPITANT; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACARBAZINE; DAUNORUBICIN; DEXAMETHASONE; DIPHENHYDRAMINE; FLUDARABINE; GEMCITABINE; GRANISETRON; HYDROXYUREA; IDARUBICIN; IRINOTECAN; LORAZEPAM; METOCLOPRAMIDE; MITOMYCIN; MITOXANTRONE; NAVELBINE; ONDANSETRON; OXALIPLATIN; PROCARBAZINE; PROCHLORPERAZINE; SEROTONIN ANTAGONIST; TEMOZOLOMIDE; UNINDEXED DRUG; VINBLASTINE;

ANOREXIA; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERANCE; HICCUP; HUMAN; INFECTION; NAUSEA; NAUSEA AND VOMITING; REVIEW; SYSTEMATIC REVIEW;

EID: 34547230098     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Aguilar EA, Figueiras MC, Cortes-Funes H, et al. Clinical practice guidelines on antiemetics in oncology. Expert Rev Anticancer Ther. 2005;5:963-972.
2. Anon. Emend Prescribing Information. Available at: http://www.emend.com/ aprepitant/emend/hcp/index.jsp (accessed July 31, 2006).
3. Bell CF, Foley KA, Pelissier JM, Hu HX, Markson LE, Berger ML. Cost consequence model: assessing the use of aprepitant vs. standard anti-emetic therapy in cancer patients undergoing highly emetogenic chemotherapy. Support Care Cancer. 2004;12. Abstract 17.
4. Bender CM, McDaniel RW, Murphy-Ende K, et al. Chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs. 2002;6:94-102.
5. Blum RA, Majumdar A, McCrea J, et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther. 2003;25:1407-1419.
6. Bokemeyer C, Oechsle K, Mueller MR, Hartmann JT, Kanz L. Aprepitant as salvage therapy in patients (pts) with chemotherapy (ctx)- induced nausea and emesis (n/v) refractory to prophylaxis with 5-HT3-antagonists and dexamethasone (dexa). J Clin Oncol. 2005;23(Suppl.). Abstract 8166.
7. Campos D, Pereira JR, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol. 2001;19:1759-1767.
8. CCOHTA (Canadian Coordinating Office for Health Technology Assessment). Aprepitant for nausea from chemotherapy. Emerging Drug List. 2003;50. Available at: http://www.ccohta.ca (accessed July 11, 2006).
9. Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer. 2003;97:2290-2300.
10. de Wit R, Herrstedt J, Rapoport B, et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol. 2003;21:4105-4111.
11. de Wit R, Herrstedt J, Rapoport B, et al. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy, a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer. 2004;40:403-410.
12. Dranitsaris G, Leung P. Using decision modeling to determine pricing of new pharmaceuticals: the case of neurokinin-1 receptor antagonist antiemetics for cancer chemotherapy. Int J Technol Assess Health Care. 2004;20:289-295.
13. Dranitsaris G, Leung P, Ciotti R, et al. A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapy. Pharmacoeconomics. 2001a;19:955-967.
14. Dranitsaris G, Leung P, Warr D. Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study. Support Cancer Care. 2001b;9:611-618.
15. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999;17:2971-2994.
16. 3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials. Cancer. 2005;104:864-868.
17. Grote T, Hajdenberg J, Cartmell A, et al. Palonosetron (PALO) plus aprepitant (APREP) and dexamethasone (DEX) for the prevention of chemotherapy-induced nausea and vomiting (CINV) after emetogenic chemotherapy (CT). J Clin Oncol. 2004;22(Suppl.). Abstract 8262.
18. Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support Care Cancer. 2005;13:80-84.
19. Herrstedt J, Aapro MS, Roila F, Kataja VV; European Society for Medical Oncology. ESMO minimum clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV). Ann Oncol. 2005a;16(Suppl. 1):i77-i79.
20. Herrstedt J, Muss HB, Warr DG, et al; Aprepitant Moderately Emetogenic Chemotherapy Study Group. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer. 2005b;104:1548-1555.
21. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4112-4119.
22. Hesketh PJ, Grunberg SM, Herrstedt J, et al. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer. 2006a;14:354-360.
23. Hesketh PJ, Younger J, Sanjay R, et al. Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide (AC). J Clin Oncol. 2006;24(Suppl.). Abstract 8618.
24. Holdsworth MT, Vo-Nguyen T. Employment of substandard antiemetic prophylaxis in recent trials of chemotherapy-induced nausea and vomiting. Ann Pharmacother. 2005;39:1903-1910.
25. Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol. 2004;15:526-536.
26. Italian Group for Antiemetic Research. Transferability to clinical practice of the results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Ann Oncol. 1998;9:759-765.
27. Kris MG, Hesketh PJ, Herrstedt J, et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer. 2005;13:85-96.
28. Kris MG, Hesketh PJ, Somerfield MR, et al. Amercican Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24:2932-2947.
29. Markman M. Progress in preventing chemotherapy-induced nausea and vomiting. Cleve Clin J Med. 2002;69:609-610, 612, 615-617.
30. MASCC (Multinational Association for Supportive Care in Cancer). Antiemetic guideline consensus. September 1, 2005. Available at: http://www.mascc.org/media/Resource_centers/MASCC_Guidelines_Update_9_05.pdf (accessed July 6, 2006).
31. Massaro AM, Lenz KL. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting. Ann Pharmacother. 2005;39:77-85.
32. Mertens WC, Higby DJ, Brown D, et al. Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol. 2003;21:1373-1378.
33. Moore SG, Turneh JW, Wojtanowski S, Flowers CR. Assessing the cost-effectiveness of adding aprepitant to the ASCO standard for prophylaxis of chemotherapy induced nausea and vomiting J Clin Oncol. 2005;23(Suppl.). Abstract 6009.
34. Navari RM, Reinhardt RR, Gralla RJ, et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med. 1999;340:190-195.
35. NCCN (National Comprehensive Cancer Network). Clinical practice guidelines in oncology. Antiemesis. v.2.2006. Available at: http://www.nccn.org/ professionals/physician_gls/PDF/antiemesis.pdf (accessed July 6, 2006).
36. O'Brien BJ, Rusthoven J, Rocchi A, et al. Impact of chemotherapy- associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. CMAJ. 1993;149:296-302.
37. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al; Aprepitant Protocol 054 Study Group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090-3098.
38. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol. 2006;17:1000-1006.
39. Sigsgaard T, Herrstedt J, Andersen LJ, et al. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy. Br J Cancer. 1999;80:412-418.
40. Sigsgaard T, Herrstedt J, Handberg J, Kjaer M, Dombernowsky P. Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. J Clin Oncol. 2001;19:2091-2097.
41. Smith AR, Repka TL, Weigel BJ. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents. Pediatr Blood Cancer. 2005;45:857-860.
42. Soukop M, McQuade B, Hunter E, et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology. 1992;49:295-304.
43. Stewart DJ, Dahrouge S, Coyle D, Evans WK. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. J Clin Oncol. 1999;17:344-351.
44. Tremont-Lukats IW, González-Barbeteo J, Bruera E, Brescia FJ. Meta-analysis of neurokinin-1 receptor antagonists (NK-1 RA) for chemotherapy-induced nausea and vomiting (CINV). J Clin Oncol. 2004;22:740s. Abstract 8047.
45. Van Belle S, Lichinitser MR, Navari RM, et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer. 2002;94:3032-3041.
46. Vanscoy GJ, Fortner B, Smith R, Weber R, Rihn TL. Preventing chemotherapy-induced nausea and vomiting: the economic implications of choosing antiemetics. Community Oncol. 2005;2:127-132.
47. Viale PH. Integrating aprepitant and palonosetron into clinical practice: a role for the new antiemetics. Clin J Oncol Nurs. 2005;9:77-84.
48. Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer. 2005a;41:1278-1285.
49. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005b;23:2822-2830.